KURA vs MA · rev $20.9M vs P/E 38, rev $17.68B
Kura Oncology Inc (KURA) versus Mastercard Inc (MA) — a side-by-side from cached financials, not a winner call.
Kura Oncology Inc (KURA) is a biotechnology company listed on NASDAQ.
Mastercard Inc (MA) is a credit services company listed on US. It is led by Michael Miebach.
Latest reported KURA revenue for 2026-06-30 was $20.9M. Net income was -$68.3M. Revenue was up 14.3% from 2026-03-31 to 2026-06-30. KURA currently screens at market cap $861.1M.
Latest reported MA revenue for 2026-06-30 was $17.68B. Net income was $8.27B. MA currently screens at market cap $515.12B and trailing P/E 38.4.
KURA currently screens at market cap $861.1M. MA currently screens at market cap $515.12B and trailing P/E 38.4.
Not investment advice. Open the KURA and MA stock pages for the full models.
Not investment advice.